Study of Safety of RVL-1201 in Treatment of Blepharoptosis
A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)
Sponsor: RVL Pharmaceuticals, Inc.
This PHASE3 trial investigates Blepharoptosis and is currently completed. RVL Pharmaceuticals, Inc. leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jun 2020 — Oct 2020 [monthly]
Completed PHASE3
-
May 2020 — Jun 2020 [monthly]
Completed PHASE3
-
May 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RVL Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .